SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2025 mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2025 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 1518 mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 1518 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 1012 mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 1012 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5% emulsion for intravenous infusion 506 mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5% emulsion for intravenous infusion 506 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

NIMODIPINE JUNO nimodipine 10 mg/50 mL concentrated intravenous infusion solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

nimodipine juno nimodipine 10 mg/50 ml concentrated intravenous infusion solution vial

juno pharmaceuticals pty ltd - nimodipine, quantity: 10 mg - injection, intravenous infusion - excipient ingredients: citric acid; sodium citrate dihydrate; water for injections; ethanol; macrogol 400 - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus, e.g., hunt and hess grades i-iii (see section 5.1 pharmacodynamic properties).

BAXTER POTASSIUM CHLORIDE 30 mmol and 0.9% SODIUM CHLORIDE 1000 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 30 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

BAXTER POTASSIUM CHLORIDE 20 mmol and 0.9% SODIUM CHLORIDE 1000 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 20 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion1950 mL biofine bag Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion1950 ml biofine bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

CSL TETANUS IMMUNOGLOBULIN-VF (human) for intravenous use 4000IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl tetanus immunoglobulin-vf (human) for intravenous use 4000iu injection vial

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

TRUXIMA rituximab (rch) 100 mg/ 10 mL concentrate solution for intravenous infusion Australia - English - Department of Health (Therapeutic Goods Administration)

truxima rituximab (rch) 100 mg/ 10 ml concentrate solution for intravenous infusion

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.